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insurance, physician type, region, pre-dialysis co-morbidities, and pre-dialysis costs 
were used to evaluate the impact of pre-dialysis paricalcitol treatment on hospitaliza-
tions, outpatient services, and medication use in ﬁrst year of dialysis. RESULTS: 
Multivariable analysis demonstrated predialysis paricalcitol use was associated 
with statistically signiﬁcant reductions in all-cause hospitalizations (0.806, 95%CI: 
0.684–0.950), all-cause outpatient services (0.953, 95%CI: 0.933–0.973) and CKD-
related hospitalizations (0.780, 95% CI: 0.635 – 0.958); CKD-related outpatient 
visits (0.962, 95% CI: 0.938–0.987); and CKD-related medications (0.922, 95% CI: 
0.852–0.996) in the ﬁrst year of dialysis compared with no predialysis VDR activator 
treatment. CONCLUSIONS: Paricalcitol treatment for SHPT prior to dialysis is 
associated with fewer CKD-related medications; and all-cause and CKD-related out-
patient services and hospitalizations in the ﬁrst year of dialysis compared to no VDR 
activator treatment. Payers should consider these ﬁndings when make coverage deci-
sions regarding the use of paricalcitol. Further studies are needed to conﬁrm these 
results.
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OBJECTIVES: The Combination of Avodart® and Tamsulosin (CombAT) study 
shows that combination therapy provides a signiﬁcantly greater degree of beneﬁt than 
tamsulosin or dutasteride monotherapy in the treatment of moderate to severe benign 
prostatic hyperplasia (BPH). The objective of this study was to assess the cost-effec-
tiveness of combination therapy with tamsulosin and dutasteride relative to either of 
monotherapies using recent information from the CombAT study. METHODS: A 
decision analytic model was constructed using a Markov model and a 1-year cycle 
time to estimate the clinical and cost consequences of tamsulosin, dutasteride, and 
combination therapy. Analyses were conducted for a 20-year time frame from the 
societal perspective. All costs are presented in 2009 US dollars, and costs and outcomes 
were discounted at a rate of 3% per year. Outcomes were expressed in terms of the 
incremental cost-effectiveness ratio (ICER), deﬁned as the ratio of additional costs to 
additional QALYs. Sensitivity analyses were conducted on model probabilities, cost 
estimates, utility values and the discount rate. RESULTS: At both moderate and severe 
symptom levels, tamsulosin was dominated by dutasteride, that is, more costly and 
less effective than dutasteride. Compared to dutasteride, combination therapy was 
more expensive but more effective with the ICERs of $197,625 for moderate symp-
toms and $241,032 for severe symptoms. However, considering a societal cost-effec-
tiveness threshold of $150,000 per QALY, combination therapy was not cost-effective 
compared to dutasteride. In most sensitivity analyses, these results were not sensitive 
to changes in model parameters. CONCLUSIONS: This study showed that tamsulosin 
was more costly and less effective than dutasteride, and the ICERs for combination 
therapy compared to dutasteride were higher than the cost-effectiveness threshold. 
Therefore, combination therapy is not cost-effective relative to dutasteride for 
moderate-to-severe BPH patients.
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OBJECTIVES: Hyperactive Bladder (HB) is a common, debilitating condition with a 
considerable negative impact on quality of life. The cost-effectiveness (CE) of three 
medications was evaluated for the treatment of patients with Hyperactive Bladder 
from the Mexican Institute of Social Security (IMSS) perspective. METHODS: CE 
analysis from the perspective of the service provider (IMSS). Since it is a chronic disease 
with different stages, a Markov model with monthly cycles in a 12-month temporal 
horizon was developed. Only direct medical costs were used in the analysis. Direct 
medical costs were estimated on a sample of patient ﬁles in two IMSS medical units. 
Criteria for inclusion was patients with more than 6 months of treatment. The effec-
tiveness measurement was taken from literature and was deﬁned as the percentage of 
patients that did not present symptoms of incontinence. Univariated and probabilistic 
sensitivity analyses were performed. RESULTS: The oxybutynin treatment reﬂected 
the lowest expected cost per patient treated for hyperactive bladder, US$545 (1 USD 
= 13.5MXN); followed by the solifenacin and tolterodine treatments, with a cost of 
US$680 and US$1,135, respectively. As for the effectiveness measurement, the percent-
age of patients that did not present incontinence within the temporal horizon of analysis 
was: with tolterodine 2.76%, with oxybutynin 7.11% and with solifenacin 7.46%. 
Therefore, cost effectiveness ratios interpreted as the cost per percentage point of 
patients that did not present HB are: oxybuynin US$77, solifenacin US$91 and tol-
terodine US$411. The incremental cost effectiveness analysis indicates that tolterodine 
is a dominated alternative and that oxybutynin and solifenacin are positioned 
within the efﬁciency line. Nonetheless, when conducting the probabilistic analysis, it 
was found that with US$411 available, a solifenacin treatment would be more cost 
effective for the institution. CONCLUSIONS: From an institutional perspective, solif-
enacine is a cost-effective alternative for treating patients with HB in the Mexican 
context.
PUK13
THE COST-EFFECTIVENESS OF EARLY SURGERY, ADDING BIOPSY, 
AND WATCHFUL WAITING IN THE MANAGEMENT OF SMALL SOLID 
RENAL MASSES: EVIDENCE FROM A MARKOV MODEL
Yu J1, Heilbrun M1, Smith K2, Zagoria R3
1University of Utah, Salt lake city, UT, USA, 2University of Pittsburgh, Pittsburgh, PA, USA, 
3Wake Forest University, Winston-Salem, NC, USA
OBJECTIVES: To compare the relative cost-effectiveness of three clinical strategies 
for managing T1a tumor (4 cm or smaller and limited to the kidney): early surgery 
upon detection of the tumor, adding percutaneous biopsy prior to surgery, and watch-
ful waiting (WW) (monitor with computerized tomography every 6 months until the 
growth is greater than 2mm per year). METHODS: A Markov decision tree was used 
to estimate the expected survival in quality-adjusted life years (QALYs) and incremen-
tal cost-effectiveness (ICER) for each strategy from a societal perspective, based on 
literature-derived estimates for the probabilities and costs of different outcomes. 
Multiple one-way and probabilistic sensitivity analysis were conducted to examine the 
robustness of the results. RESULTS: In the base-case, adding biopsy before surgery 
improved survival by 0.018 QALYs compared with immediate surgery, at an incre-
mental cost of $55,244/QALY, while the ICER of WW relative to surgery was 
$11,712/QALY. In the base-case, percutaneous biopsy is more expensive and less 
effective than WW. The treatment decision was most sensitive to variation of the 
degree of tumor growth that triggers surgery, utility of living with a mass during WW, 
and the probability of diagnostic biopsy for benign tumors. Choice of WW versus 
surgery critically depends on patients’ preferences for tumor removal and the risk of 
recurrence post surgery. In probabilistic sensitivity analysis, surgery was the most 
favored strategy when the willingness to pay (WTP) is less than $10,000/QALY. WW 
is favored as WTP increases beyond $10,000/QALY, and biopsy was favored over 
surgery when WTP is > $60,000. CONCLUSIONS: Although WW results in the 
highest life-time utility, the favorability of WW depends on patients’ preferences for 
living with a possibly malignant mass and natural history of watched masses during 
surveillance, which are poorly understood. Biopsy would be favored if its costs 
decrease and diagnostic certainty increases in the future.
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OBJECTIVES: Therapies that extend the lives of dialysis patients can not demonstrate 
cost-effectiveness if dialysis costs are included. This study examined the cost-effective-
ness of sevelamer versus calcium-based binders (CBBs) as treatment for hyperphos-
phatemia in dialysis patients and, within this context, the suitability of the inclusion 
of dialysis costs. METHODS: A Markov model estimated life years, incremental cost 
per life year gained (LYG) and incremental quality-adjusted life year gained (QALYG). 
Treatment-speciﬁc survival was derived from the Dialysis Clinical Outcomes Revisited 
(DCOR) study and extrapolated using a Weibull regression model. The base case 
analysis used resource use and survival data for DCOR patients ≥65 years combined 
with Canadian unit costs and utility weights from published literature. Dialysis costs 
were excluded from the base case analysis, as dialysis use is unrelated to phosphate 
binder choice. Analyses were conducted for a 10-year time horizon using the Alberta 
Health Care System perspective, with costs and outcomes discounted at 5% per year. 
RESULTS: Compared with CBBs, sevelamer resulted in a gain of 1.02 LYs and 
0.62 QALYs/ patient (discounted) producing ratios of $20,847/LYG and $34,175/
QALYG. Over a lifetime horizon, the cost/LYG and cost/QALYG were $23,804 and 
$39,022, respectively. Inclusion of dialysis costs resulted in ratios above $90,000/LYG 
and $150,000/QALYG. CONCLUSIONS: The study highlights the challenges associ-
ated with assessing funding of therapies that extend life in dialysis patients and dis-
cusses the applicability of dialysis costs in such situations. It found that sevelamer 
offers good value for money compared to CBBs in the treatment of hyperphosphatemia 
in patients ≥65 years old receiving dialysis.
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OBJECTIVES: Six pharmacological agents are FDA-approved to treat urinary incon-
tinence, a condition that has economic costs of $19 billion US dollars per year. This 
study compares the recently FDA-approved fesoterodine to generic oxybutynin 
extended-release (ER) to identify which agent is more cost-effective in the treatment 
of urinary incontinence for three months in women over age 60 from the third party 
payer perspective. METHODS: A search was conducted using the MEDLINE Data-
base from 1980–2009 for the terms “oxybutynin,” “fesoterodine,” “randomized 
controlled trial,” and “urinary incontinence.” Five articles evaluating clinical improve-
ment among a predominantly female population were identiﬁed for inclusion. For the 
purpose of this analysis, an effectively treated patient was deﬁned as a patient dem-
onstrating a decrease of 14 or more episodes per week of each of the following: urge 
